BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...

Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Adds Pfizer statement. BridgeBio (BBIO) fell 1.3% after originally gaining 11% as a court filing disclosed a settlement in a ...

CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1. PALO ALTO, ...

Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...

Showcase your company news with guaranteed exposure both in print and online Gather your employees for an afternoon of fun as we honor the Denver metro area… A panel of dynamic developers and leaders ...

Henry Ford and the Ford Motor Company have not only revolutionized the automotive industry but also helped shape the American economy over the last 120+ years. Ford is one of the largest manufacturers ...